Pre-Clinical Studies

In Vitro Radioligand Receptor/Immuno-Binding Assays

Radioligand receptor binding assay is to study the affinity of receptors, the number of receptors, etc. by using radioactive isotope labeled ligands to bind specifically to the corresponding receptors.

Pharmacokinetics/Bio-distribution

By radioisotope 125I labeling technology, combined with gamma counting detection methods, MITRO provides accurate quantitative in vitro ADME study services.

Receptor Occupancy

Molecular imaging technology is an important research method for neurological diseases. MITRO can not only perform radioisotope labeling for neurological drugs to study drug penetration through the blood-brain barrier but provide corresponding radiotracer R&D/preparation services according to different drug targets.

Pharmacodynamics

For cardiovascular and cerebrovascular drugs, MITRO can observe the subtle changes of drugs in local areas and the dynamic distribution of the whole body in real time by applying molecular imaging technology. At the same time, due to the advantages of high sensitivity of molecular imaging technology, even the lesion sites of millimeter magnitude can be clearly imaged, which provides important basis for enterprises to explore disease mechanism, develop diagnosis and treatment drugs, evaluate treatment effect, etc.

Toxicity of Radiopharmaceuticals

Through the application of radiolabeling and molecular imaging technology, we provide customers at home and abroad with overall solutions and outsourcing technical services for drug screening, biodistribution, pharmacokinetic research, pharmacodynamic evaluation and other new drug research and development.

MITRO Biotech Co., Ltd.

Telephone: +86-25-52118501

E-mail: info@mi-tro.com

Address: Building 8, Qiande Road, Jiangning Science Park, Nanjing, Jiangsu Province, China

MITRO Official Account

Business License